Form 4: Zevra Therapeutics Director Tamara Favorito Granted 30,000 Stock Options

Tamara A. Favorito, a Director at Zevra Therapeutics, Inc., was granted 30,000 stock options with an exercise price of $8.62 as part of her compensation for board service.

Summary

• Tamara A. Favorito, a Director of Zevra Therapeutics, Inc. (ZVRA), was granted 30,000 stock options.
• The options were granted on May 29, 2025, with an exercise price of $8.62 per share, which is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the grant date.
• This grant serves as compensation for Ms. Favorito's service on the Issuer's board of directors, consistent with Zevra Therapeutics' tenth amended and restated non-employee director compensation policy.
• The options are set to expire on May 28, 2035.
• Vesting of 100% of the shares subject to the option will occur on the earliest of: (i) the first anniversary of the grant date, (ii) the day prior to the first annual stockholders meeting after the grant date, or (iii) immediately prior to a change in control of the Issuer, contingent upon Ms. Favorito's continued service on the vesting date.

Sentiment

Score: 7

Explanation: The document reports a routine compensation grant to a director, which is a positive for aligning interests but does not indicate extraordinary news. The grant is expected and part of standard corporate governance.

Positives

• The grant of stock options aligns the interests of Director Tamara A. Favorito with those of the shareholders, as the value of her compensation is tied to the company's stock performance.
• The compensation is part of a pre-existing, publicly disclosed non-employee director compensation policy, indicating a structured and transparent approach to executive remuneration.

Future Outlook

The future outlook regarding these options is tied to their vesting schedule, which is contingent on the director's continued service and specific corporate events such as the first anniversary of the grant, the next annual stockholders meeting, or a change in control.

Management Comments

• The grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

Industry Context

The granting of stock options to non-employee directors is a common practice across various industries, including the biotechnology and pharmaceutical sectors, serving to align the interests of board members with those of shareholders and to attract and retain qualified talent.

Comparison to Industry Standards

• The practice of compensating non-employee directors with equity, such as stock options, is a standard corporate governance practice across publicly traded companies, including those in the biotechnology sector like Zevra Therapeutics.
• The vesting schedule, which includes time-based vesting (one year anniversary) and event-based vesting (annual meeting or change in control), is typical for director equity awards, aiming to ensure continued service and incentivize long-term value creation.
• The exercise price being set at the closing market price on the grant date is a common method for granting 'at-the-money' options, which are standard in director compensation plans.

Corporate Governance

Related Party Transactions

• The grant of stock options to Tamara A. Favorito, a Director, constitutes a related party transaction, which is disclosed as part of her compensation for board service.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options gain value if the stock price increases.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will vest based on the earlier of the first anniversary of the grant date, the day prior to the first annual stockholders meeting after the grant date, or immediately prior to a change in control of the Issuer, subject to continued service.

Key Dates

Recommendation

Keywords

ZEVRA THERAPEUTICS, ZVRA, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, Corporate Governance